The materials provided on this page were presented at scientific meetings or publications made in scientific journals and are shared to support scientific exchange. They may include nonclinical, exploratory, or hypothesis generating data.
These materials are not promotional and do not replace the FDA approved Prescribing Information for any product.
2026
Society of Toxicology Annual Meeting, March 2026
Poster 4331: Correlation of Dietary Antioxidant Levels to Incidence and Severity of Oteseconazole Induced Nuclear Opacities in Peri-Postnatal Development (PPND) Studies
Poster 4332: Dietary Vitamin-K Dependent Coagulopathy and Ocular Bleeding Events in Rat Pups Treated with Oteseconazole During PPND Studies
Poster 4039: A Sliding Scale to Evaluate Safety Margins for Drugs with Long Half-Life: Oteseconazole, A Case Study
2025
Journal of Women’s Health
2 Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis – Published November 2025
2023
Antimicrobial Agents and Chemotherapy
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial – Published December 2023
2022
American Journal of Obstetrics & Gynecology
Phase 3 Study Evaluating the Safety and Efficacy of Oteseconazole in the Treatment of Recurrent Vulvovaginal Candidiasis and Acute Vulvovaginal Candidiasis Infections — Published December 2022
Infectious Diseases Society for Obstetrics and Gynecology, August 2022
Poster: Long-term Observations of Oteseconazole Efficacy Against Recurrent Vulvovaginal Candidiasis
New England Journal of Medicine Evidence
Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis – Published July 2022
